Attached files
file | filename |
---|---|
EX-99.1 - PRESS RELEASE DATED DECEMBER 4, 2017 - AzurRx BioPharma, Inc. | azrx_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): December 4,
2017
AZURRX BIOPHARMA, INC.
|
|
|
Delaware
|
001-37853
|
46-4993860
|
(State
or Other Jurisdiction of
Incorporation
or Organization)
|
(Commission
File Number)
|
(I.R.S.
Employer
Identification
No.)
|
760 Parkside Avenue
Downstate Biotechnology Incubator,
Suite 304
Brooklyn, New York
|
|
11226
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s telephone number, including area code:
(646) 699-7855
(Name,
address, including zip code, and telephone number, including area
code, of agent for service of process)
NOT
APPLICABLE
(Former
Name or Former Address, if Changes Since Last Report)
Check
the appropriate box below if the Form 8-K is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions):
[
] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[
] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
[
] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[
] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of
the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of
this chapter).
Emerging
growth company [X]
If an
emerging growth company, indicate by checkmark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
[
]
Item 8.01
Other Events
On
December 4, 2017, the Company issued a press release announcing
the
Company will be making a presentation at the Biotech Showcase
conference in San Francisco at the Hilton San Francisco Union
Square Hotel, on Monday, January 8th at 10:00 a.m.
PST. A copy of the press release is attached to this Current
Report on Form 8-K as Exhibit 99.1.
Item
9.01
Financial
Statements and Exhibits
(d) Exhibits.
Exhibit No.
|
|
Description
|
|
Press
Release dated December 4, 2017
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this Report to be signed on its behalf
by the undersigned hereunto duly authorized.
AzurRx BioPharma, Inc.
|
Date:
December 4,
2017
By:
|
/s/
Johan M. Spoor
|
Name: Johan M. Spoor
|
|
Title: Chief Executive Officer
|
Exhibit Index